Get the Stockscreener App
0.29
1.29%
-0.0038
After Hours:
.29
Intensity Therapeutics Inc stock is traded at $0.29, with a volume of 5.21M.
It is down -1.29% in the last 24 hours and down -12.91% over the past month.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
See More
Previous Close:
$0.2938
Open:
$0.3098
24h Volume:
5.21M
Relative Volume:
1.53
Market Cap:
$13.65M
Revenue:
-
Net Income/Loss:
$-16.26M
P/E Ratio:
-0.2455
EPS:
-1.1814
Net Cash Flow:
$-13.50M
1W Performance:
+6.34%
1M Performance:
-12.91%
6M Performance:
-86.64%
1Y Performance:
-93.12%
1-Day Range:
$0.2802
$0.32
1-Week Range:
$0.2453
$0.32
52-Week Range:
$0.1853
$4.43
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.29 | 13.83M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Intensity Therapeutics Inc Stock (INTS) Latest News
Intensity Therapeutics Inc (INTS) Stock: Navigating a Year of Volatility - investchronicle.com
Shelton-based biotech regains Nasdaq compliance - Hartford Business Journal
Is now a turning point for Intensity Therapeutics Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - Newser
Analyzing recovery setups for Intensity Therapeutics Inc. investors [Weekly Gains Report]Free Safe Capital Growth Stock Tips - Newser
Analyzing recovery setups for Intensity Therapeutics Inc. investorsHigh Accuracy Trade Setup Identification - Newser
Intensity (INTS) Q2 Net Loss Drops 50% - AOL.com
Intensity Therapeutics Amends Bylaws for Quorum Change - MSN
Sentiment analysis tools applied to Intensity Therapeutics Inc.Free Triple Digit Return Stock Predictions - Newser
Can momentum traders help lift Intensity Therapeutics Inc.New Guidance & Real-Time Market Trend Scan - Newser
How to recover losses in Intensity Therapeutics Inc. stock [2025 Pullback Review]Free Community Trade Idea Sharing Platform - Newser
Brookline Capital upgrades Intensity Therapeutics stock rating to Buy By Investing.com - Investing.com Australia
Using data filters to optimize entry into Intensity Therapeutics Inc.Value Investing Summary and Earnings Outlook - Newser
Intensity Therapeutics regains compliance with Nasdaq listing requirements By Investing.com - Investing.com Nigeria
Intensity Therapeutics regains compliance with Nasdaq listing requirements - Investing.com
Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - WV News
Intensity Therapeutics shares fall 2.96% premarket as health care sector sees mixed performance. - AInvest
How Intensity Therapeutics Inc. stock performs during market volatilityFree Stock Market Watch With Alerts - Newser
Using Python tools to backtest Intensity Therapeutics Inc. strategiesSwing Trade Entry and Exit Point Analysis - Newser
Why Intensity Therapeutics Inc. stock attracts strong analyst attentionBuy and Hold Position Summary Review - Newser
Multi factor analysis applied to Intensity Therapeutics Inc.Intraday Movement Recap and Chart Summary - Newser
Is Intensity Therapeutics Inc. still worth holding after the dipStock Portfolio Risk and Return Analysis - Newser
Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Morningstar
Is Intensity Therapeutics Inc. meeting your algorithmic filter criteriaTechnical Insight Guide for Safer Trades - Newser
Shelton biotech raises millions for novel cancer treatment - Hartford Business Journal
How to recover losses in Intensity Therapeutics Inc. stockLow Risk Strategy with Smart Entry Zones - Newser
why intensity therapeutics inc. stock attracts strong analyst attentionAI-Based Reversal Point Prediction Signal - Newser
Intensity Therapeutics Raises $6.6 Million in July Offering - TipRanks
Intensity Therapeutics Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - investchronicle.com
Intensity Therapeutics raises $6.6M from ATM stock sales in July - TipRanks
Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025 - Citizen Tribune
Biotech Intensity Therapeutics Secures $6.6M Funding at Premium Price, Extends Operations Through 2026 - Stock Titan
Intensity Therapeutics Inc.’s Beta Climbs After Market VolatilityChart Driven High Reward Trading Setup Presented - beatles.ru
Is Intensity Therapeutics Inc. stock overvalued or undervaluedBuild wealth faster with consistent investment plans - Jammu Links News
What analysts say about Intensity Therapeutics Inc. stockUnlock superior stock analysis tools - Jammu Links News
What are analysts’ price targets for Intensity Therapeutics Inc. in the next 12 monthsFree Trading Psychology Coaching - Jammu Links News
Is Intensity Therapeutics Inc. a good long term investmentFree Stock Selection - Jammu Links News
How does Intensity Therapeutics Inc. generate profit in a changing economyMaximize your returns with expert insights - Jammu Links News
Is it the right time to buy Intensity Therapeutics Inc. stockTremendous growth opportunities - Jammu Links News
How strong is Intensity Therapeutics Inc. company’s balance sheetMaximize your returns with portfolio optimization - Jammu Links News
What catalysts could drive Intensity Therapeutics Inc. stock higher in 2025Consistent high-yield stocks - Jammu Links News
What drives Intensity Therapeutics Inc. stock priceRobust investment performance - Jammu Links News
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):